Expression and prognostic value of the Ki-67 in Wilms' tumor: experience with 48 cases
- PMID: 20306058
- DOI: 10.1007/s00383-010-2588-3
Expression and prognostic value of the Ki-67 in Wilms' tumor: experience with 48 cases
Abstract
Purpose: Ki-67, tumor proliferation marker, is an important prognostic factor in a variety of cancers. In the present study, we investigated the expression and the prognostic value of Ki-67 in nephroblastoma.
Methods: Ki-67 expressions were investigated by immunohistochemistry on paraffin-embedded material in 48 children operated on because of nephroblastoma. Patients were treated according to SIOP protocol. The mean follow-up period was 5.4 years. A proliferation index was obtained by immunohistochemistry using anti-Ki-67 anti-body.
Results: The mean Ki-67 proliferation index in the blastemal type was 12.3%, and in the epithelial type, 21.4%. In the anaplastic type, Ki-67 proliferation index was: in the blastemal component 20%, in the stromal 21%, and in the epithelial 31%. In the mixed tumor type, Ki-67 proliferation index was assessed as: in the blastemal component 10%, in the epithelial 33% and in the stromal 31.5%. Proliferation index for the epithelium was significantly higher than those found for the blastema (P = 0.001). A correlation between Ki-67 and tumor stage found proliferation index significantly higher in stages I and II (P = 0.002).
Conclusion: The results support the conclusion that Ki-67 is a relevant marker for assessing the proliferative activity and tumor cell dynamics of nephroblastoma, but it may not be a good clinical prognostic marker.
Similar articles
-
MIB-1 (KI-67) proliferation index and cyclin-dependent kinase inhibitor p27(Kip1) protein expression in nephroblastoma.Clin Cancer Res. 2004 Jan 15;10(2):591-7. doi: 10.1158/1078-0432.ccr-0884-02. Clin Cancer Res. 2004. PMID: 14760081
-
High cyclin E staining index in blastemal, stromal or epithelial cells is correlated with tumor aggressiveness in patients with nephroblastoma.PLoS One. 2008 May 21;3(5):e2216. doi: 10.1371/journal.pone.0002216. PLoS One. 2008. PMID: 18493303 Free PMC article.
-
Minichromosome maintenance 2 (MCM2) is a new prognostic proliferative marker in Wilms tumour.Pol J Pathol. 2011;62(2):84-8. Pol J Pathol. 2011. PMID: 21866463
-
Adult extrarenal Wilms' tumor mimicking mixed epithelial and stromal tumor in the retroperitoneum: a case report with immunohistochemical study and review of the literature.Pathol Oncol Res. 2009 Dec;15(4):665-9. doi: 10.1007/s12253-009-9169-6. Epub 2009 Apr 24. Pathol Oncol Res. 2009. PMID: 19390992 Review.
-
Nephroblastoma (Wilms' tumor): a model system of aberrant renal development.Semin Diagn Pathol. 1994 May;11(2):126-35. Semin Diagn Pathol. 1994. PMID: 7809506 Review.
Cited by
-
Does immunohistochemical staining of P53, Ki 67 and cyclin A accurately predict Wilms tumor recurrence and survival?Arab J Urol. 2022 Apr 11;20(3):107-114. doi: 10.1080/2090598X.2022.2058240. eCollection 2022. Arab J Urol. 2022. PMID: 35935912 Free PMC article.
-
Telomerase reverse transcriptase catalytic subunit expression and proliferation index in Wilms tumor.Tumour Biol. 2011 Aug;32(4):761-7. doi: 10.1007/s13277-011-0178-1. Epub 2011 May 8. Tumour Biol. 2011. PMID: 21553236
-
Wilms' Tumor: A Review of Clinical Characteristics, Treatment Advances, and Research Opportunities.Medicina (Kaunas). 2025 Mar 12;61(3):491. doi: 10.3390/medicina61030491. Medicina (Kaunas). 2025. PMID: 40142302 Free PMC article. Review.
-
Evaluation of diagnostic utility of imprint cytology in paediatric renal tumours with special references to Ki 67 proliferative marker.J Lab Physicians. 2018 Oct-Dec;10(4):437-442. doi: 10.4103/JLP.JLP_157_17. J Lab Physicians. 2018. PMID: 30498318 Free PMC article.
-
Mutational analysis of extranodal marginal zone lymphoma using next generation sequencing.Oncol Lett. 2020 Nov;20(5):205. doi: 10.3892/ol.2020.12068. Epub 2020 Sep 8. Oncol Lett. 2020. PMID: 32963611 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical